Suspension of trading
Intellipharmaceutics International Inc. Stock
Stocks
I4AA
CA4581733090
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0445 EUR | -13.59% |
|
-.--% | - |
| Market Cap | 1.28M 1.1M 1.02M 955K 1.79M 121M 1.81M 11.99M 4.68M 59.31M 4.81M 4.71M 206M | P/E Ratio 2021 |
-0.4x | P/E Ratio 2022 | -0.91x |
|---|---|---|---|---|---|
| Enterprise Value | 3.52M 3.04M 2.79M 2.63M 4.93M 333M 4.99M 32.96M 12.86M 163M 13.22M 12.94M 565M | EV / Sales 2021 |
-
| EV / Sales 2022 | 74x |
| Free-Float |
98.24% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 day | -13.59% |
| 3 years | 0.02 |  | 0.08 |
| 5 years | 0.01 | | 0.18 |
| 10 years | 0.01 | | 35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Amina Odidi
DFI | Director of Finance/CFO | - | - |
| Comptroller/Controller/Auditor | - | 2007-03-31 | |
| Corporate Officer/Principal | - | 2014-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Amina Odidi
BRD | Director/Board Member | - | 2004-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24-02-13 | Option | Director | 100,000 | 0.3022% | ||
| 24-02-12 | Option | Director | 120,000 | 0.3626% | ||
| 24-02-12 | Option | Chief Executive Officer | 500,000 | 1.5109% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -13.59% | -.--% | -.--% | +2.30% | 1.52M | |
| -0.61% | -2.32% | +37.00% | +147.28% | 1,007B | |
| -0.20% | +1.30% | +49.70% | +43.64% | 567B | |
| +0.40% | -0.27% | +16.43% | +63.71% | 392B | |
| -1.18% | +1.05% | +20.91% | +18.37% | 328B | |
| -0.43% | +2.01% | +23.20% | +32.46% | 277B | |
| +0.64% | -3.71% | +20.92% | +13.67% | 275B | |
| -1.86% | +3.05% | -45.70% | -49.24% | 196B | |
| -0.77% | +0.61% | +17.82% | +52.27% | 189B | |
| +2.36% | -0.68% | +15.68% | +61.05% | 154B | |
| Average | -1.43% | +0.19% | +15.60% | +38.55% | 338.6B | |
| Weighted average by Cap. | -0.04% | -0.03% | +25.91% | +66.88% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | - | 65.73K 56.62K 52.12K 48.97K 91.97K 6.22M 93.05K 615K 240K 3.04M 247K 241K 10.54M |
| Net income | -5.15M -4.43M -4.08M -3.83M -7.2M -487M -7.28M -48.14M -18.77M -238M -19.31M -18.9M -825M | -2.89M -2.49M -2.29M -2.16M -4.05M -274M -4.09M -27.06M -10.55M -134M -10.85M -10.62M -464M |
| Net Debt | 1.15M 987K 908K 853K 1.6M 108M 1.62M 10.72M 4.18M 53.02M 4.3M 4.21M 184M | 2.24M 1.93M 1.78M 1.67M 3.14M 212M 3.17M 20.98M 8.18M 104M 8.41M 8.24M 360M |
Employees
11
Sector
Pharmaceuticals
- Stock Market
- Stocks
- I4AA Stock
Select your edition
All financial news and data tailored to specific country editions
